KalVista Pharmaceuticals

creating a new generation of small molecule protease inhibitors for HAE and DME

KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer

KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824